Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15798MR)

This product GTTS-WQ15798MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Hematologic-blood cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15798MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1331MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ12011MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ9389MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ12293MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ6546MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ7132MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ3893MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ11298MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-522
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW